stella
beta
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas — Stella
Recruiting
Back to Lymphoma, T-Cell trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(2 sites)
China
Institute of Hematology & Blood Diseases Hospital, China, Tianjin, Tianjin Municipality
Institute of Hematology & Blood Diseases Hospital, Tianjin
View full record on ClinicalTrials.gov